Research shows how 'Mallard' dye fills need for speedFebruary 14, 2013
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood. Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.
In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.
The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.
Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.
Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.
"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."
The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.
The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.
University of York
Related Heparin Articles:
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.
An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occurrence of dangerous blood clots.
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.
China's appetite for pigs fills dinner plates, but it also fills half the world's orders for heparin, an anticoagulant made from the animals' intestines.
As demand for the widely used blood-thinning drug heparin continues to grow, experts worry of possible shortages.
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung conditions, and for certain surgeries.
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
A large, ambitious contrast of blood-thinning medications used during cardiac stent placement suggests that a very expensive drug offers no clear safety benefits over a much more affordable option, according to a prominent North Shore-LIJ researcher and cardiologist.
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for six months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the Aug.
A Northwestern University research team attached a gas molecule to protamine sulfate, creating a new nitric oxide generator that could potentially reduce bleeding complications during surgery.
Related Heparin Reading:
Target audience: Medical students, residents, healthcare workers, patients
Weekly updates? Yes
Multiple choice questions? Yes
Board review? Yes View Details
Heparin-Induced Thrombocytopenia, Fifth Edition (Fundamental and Clinical Cardiology)
by Theodore E. Warkentin (Editor), Andreas Greinacher (Editor)
Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this condition. Identifying key signs and symptoms and providing clear intervention strategies―including the use of alternative anticoagulants to manage critical circumstances―this is an essential resource for all clinicians and a "must" for... View Details
Heparin - A Century of Progress (Handbook of Experimental Pharmacology)
by Rebecca Lever (Editor), Barbara Mulloy (Editor), Clive P. Page (Editor)
Heparins remain amongst the most commonly used drugs in clinical practice. Almost 100 years have passed since the initial discovery of this complex substance and, during this time, understanding of the nature and uses of heparin and related molecules has grown dramatically. The aim of this volume is to summarise the developments that have led to the current status of both heparins as drugs and the field of heparin research, with a focus on the particularly rapid progress that has been made over the past three decades. Individual sections are dedicated to the nature of heparin as a... View Details
Williams Hematology, 9E
by Kenneth Kaushansky (Author), Marshall A. Lichtman (Author), Josef Prchal (Author), Marcel M. Levi (Author), Oliver W Press (Author), Linda J Burns (Author), Michael Caligiuri (Author)
The world's most highly regarded reference text on the mechanisms and clinical management of blood diseases
A Doody's Core Title for 2017!
Edition after edition, Williams Hematology has guided generations of clinicians, biomedical researchers, and trainees in many disciplines through the origins, pathophysiological mechanisms, and management of benign and malignant disorders of blood cells and coagulation proteins. It is acknowledged worldwide as the leading hematology resource, with editors who are internationally regarded for... View Details
Heparin : chemistry and clinical usage
by King's College Hospital Medical School, 1975. Kakkar, V. V. ; Thomas, Duncan P., International Heparin Symposium (Author)
Heparin : structure, function, and clinical implications : [proceedings]
by Mo.) (1974 : Bradshaw, Ralph A., ; Wessler, Stanford, International Symposium on Heparin Saint Louis (Author)
by Hodder Arnold (Publisher)
Heparin: metabolism, physiology and clinical application.
by H. Brown, Kenneth D. Engelberg (Author)
Heparin: U.S. Edition
by D LANE (Author), U. Lindahl (Author)
Heparin: Swedish Edition
by D LANE (Author), U. Lindahl (Author)